NCT06892379View on ClinicalTrials.gov

A Study of HS-20110 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2027

Conditions
Solid Tumors
Interventions
DRUG

HS-20110 (Phase Ia：Dose escalation )

HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles

DRUG

HS-20110 (Phase Ib:Dose expansion )

The recommended dose from the dose-escalation stage and other potential doses will be further explored

Trial Locations (3)

33321

RECRUITING

BRCR Medical Center INC, Tamarac

77030

NOT_YET_RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

510000

RECRUITING

SUN YAT-SEN University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY